Keytruda® (pembrolizumab) – Indication withdrawal
March 1, 2021 - Merck announced the voluntary withdrawal of the Keytruda (pembrolizumab) indication for treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
Top